Publication date: Available online 23 April 2017
Source:Brachytherapy
Author(s): Matthew W. Jackson, Arya Amini, Bernard L. Jones, Brian Kavanagh, Paul Maroni, Steven J. Frank, Usama Mahmood, Rajat J. Kudchadker, Thomas J. Pugh
PurposeConventional prostate cancer risk stratification results in considerable heterogeneity within each prognostic group. Men with pathologic grade Group 4 (Gleason score 8) but otherwise low-risk features have been identified as a favorable subset of high-risk prostate cancer. Given recent randomized data supporting improved cancer outcome with brachytherapy in intermediate- and high-risk prostate cancer, we sought to evaluate brachytherapy utilization and overall survival (OS) for these patients.Methods and MaterialsWe queried the National Cancer Database for clinical T1c–T2a N0 M0 prostate cancer with prostate-specific antigen <10 ng/mL and Gleason score 8 adenocarcinoma on biopsy. All patients received androgen deprivation therapy and either external beam radiation therapy (EBRT) alone, brachytherapy alone, or a combination of EBRT with brachytherapy boost (brachytherapy + EBRT). Kaplan–Meier OS estimates as well as univariate and multivariate Cox proportional hazards regression analyses were performed. Propensity score–matched analyses were performed to further control for baseline confounders.ResultsFour thousand four hundred ninety-six patients were identified with a median followup of 62.5 months (range, 2.3–119.8). Median age was 72 years (range, 41–90+). Utilization of brachytherapy decreased from 2004 to 2009. The odds ratio for brachytherapy by year (continuous variable) was 0.86 (p < 0.001). Five-year OS was 84%, 88%, and 89% for the EBRT alone, brachytherapy alone, and brachytherapy + EBRT groups, respectively. On multivariate analysis, higher median income, low comorbidity score, and treatment with brachytherapy alone (hazard ratio, 0.66; p = 0.005) or brachytherapy + EBRT (hazard ratio, 0.70; p = 0.001) remained associated with longer OS. Propensity score matching confirmed longer OS associated with either brachytherapy regimen.ConclusionsOf those men with World Health Organization pathologic grade Group 4 (Gleason score 8) prostate cancer and otherwise favorable prognostic features treated with androgen deprivation therapy and radiation therapy, longer OS was achieved when prostate brachytherapy was included, whether used alone or in combination with supplemental EBRT. In spite of these excellent outcomes, prostate brachytherapy utilization is declining in the United States.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2pTrMTV
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Abstract BACE1 is an indispensable enzyme for generating β-amyloid peptides, which are excessively accumulated in brains of Alzheimer'...
-
Publication date: Available online 23 April 2017 Source: Journal of Plastic, Reconstructive & Aesthetic Surgery Author(s): Yu-Jen Chiu...
-
Objective To identify the injury history features reported by patients with anterior cruciate ligament (ACL) injuries and determine whether ...
-
Rhinoplasty is perhaps the most challenging and elegant procedure within all of plastic surgery. In this issue of JAMA Facial Plastic Surger...
-
Science Daily Scientists develop light-controllable tool to study CaMKII kinetics in learning and memory Science Daily In summary, t...
-
AMEDEO Otorhinolaryngologyhttp://www.amedeo.comhttp://m.amedeo.com2019-10-07Your Personal Amedeo Web... AMEDEO Otorhinolaryngologyhttp://www...
-
Publication date: October 2017 Source: International Journal of Biological Macromolecules, Volume 103 Author(s): Sapna, Bijender Singh A...
-
This Viewpoint discusses variances in cardiovascular prevention guidelines from the United States, Europe, and Canada and the debate surroun...
-
Three-Dimensional Printing and Its Applications in Otorhinolaryngology-Head and Neck Surgery. Otolaryngol Head Neck Surg. 2016 Nov 01;...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου